FDA NDA · NDA021252

CANASA

mesalamine

Sponsor: ABBVIE

What this page does not claim

A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.

APPLICATION
NDA021252
TYPE
NDA
ORIGINAL APPROVAL
2001-01-05
LATEST ACTION
2026-10-14
ROUTE
RECTAL
DOSAGE FORM
SUPPOSITORY
MARKETING STATUS
Discontinued, Prescription

Products

CANASADiscontinued
MESALAMINE 500MG · SUPPOSITORY · RECTAL
CANASA · ReferencePrescription
MESALAMINE 1GM · SUPPOSITORY · RECTAL

Approval history

2026-10-14Labeling · Supplement 31 · standard — Letter ↗AP
2023-10-24Labeling · Supplement 30 · standard — Label ↗AP
2022-11-16Labeling · Supplement 29 · standard — Letter ↗AP
2021-11-01Labeling · Supplement 28 · standard — Letter ↗AP
2020-10-01Labeling · Supplement 25 · standard — Letter ↗AP
2017-07-27Labeling · Supplement 23 · standard — Label ↗AP
2016-09-02Efficacy · Supplement 14 · priority — Label ↗AP
2014-07-30Manufacturing (CMC) · Supplement 21 · priorityAP
2014-01-02Manufacturing (CMC) · Supplement 19 · priorityAP
2013-12-24Manufacturing (CMC) · Supplement 18 · priorityAP
2013-12-17Labeling · Supplement 20 · standard — Label ↗AP
2013-05-03Manufacturing (CMC) · Supplement 16 · priorityAP
2013-02-06Labeling · Supplement 13 · unknown — Label ↗AP
2008-05-23Manufacturing (CMC) · Supplement 9 — Letter ↗AP
2006-06-08Labeling · Supplement 7 · standard — Letter ↗AP
2004-11-05Efficacy · Supplement 5 · standard — Letter ↗AP
2004-09-23Labeling · Supplement 6 · standard — Letter ↗AP
2003-10-14Labeling · Supplement 2 · standard — Letter ↗AP
2001-01-05Type 5 - New Formulation or New Manufacturer · Original · priority — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →